Legislators React to Eli Lilly Insulin Price Cap
SAINT PAUL, Minn. — On Wednesday, pharmaceutical manufacturer Eli Lilly announced its decision to cap out-of-pocket insulin costs at $35 monthly per recipient. The company’s move follows federal legislation to limit the maximum copay for people enrolled in Medicare at the same monthly amount. In Minnesota, the Alec Smith Insulin Affordability Act of 2020 ensured that patients could receive at least one month’s worth of their insulin for a maximum of $35, with a long-term limit of $50 out-of-pocket per 90 days for eligible recipients.